Literature DB >> 17060617

Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes.

Keshava Rajagopal1, Erin J Whalen, Jonathan D Violin, Jonathan A Stiber, Paul B Rosenberg, Richard T Premont, Thomas M Coffman, Howard A Rockman, Robert J Lefkowitz.   

Abstract

The G protein-coupled receptor kinases (GRKs) and beta-arrestins, families of molecules essential to the desensitization of G protein-dependent signaling via seven-transmembrane receptors (7TMRs), have been recently shown to also transduce G protein-independent signals from receptors. However, the physiologic consequences of this G protein-independent, GRK/beta-arrestin-dependent signaling are largely unknown. Here, we establish that GRK/beta-arrestin-mediated signal transduction via the angiotensin II (ANG) type 1A receptor (AT(1A)R) results in positive inotropic and lusitropic effects in isolated adult mouse cardiomyocytes. We used the "biased" AT(1A)R agonist [Sar(1), Ile(4), Ile(8)]-angiotensin II (SII), which is unable to stimulate G(alpha)q-mediated signaling, but which has previously been shown to promote beta-arrestin interaction with the AT(1A)R. Cardiomyocytes from WT, but not AT(1A)R-deficient knockout (KO) mice, exhibited positive inotropic and lusitropic responses to both ANG and SII. Responses of WT cardiomyocytes to ANG were dramatically reduced by protein kinase C (PKC) inhibition, whereas those to SII were unaffected. In contrast, cardiomyocytes from beta-arrestin2 KO and GRK6 KO mice failed to respond to SII, but displayed preserved responses to ANG. Cardiomyocytes from GRK2 heterozygous knockout mice (GRK2(+/-)) exhibited augmented responses to SII in comparison to ANG, whereas those from GRK5 KO mice did not differ from those from WT mice. These findings indicate the existence of independent G(alpha)q/PKC- and GRK6/beta-arrestin2-dependent mechanisms by which stimulation of the AT(1A)R can modulate cardiomyocyte function, and which can be differentially activated by selective receptor ligands. Such ligands may have potential as a novel class of therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17060617      PMCID: PMC1637574          DOI: 10.1073/pnas.0607583103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  The ankyrin-B C-terminal domain determines activity of ankyrin-B/G chimeras in rescue of abnormal inositol 1,4,5-trisphosphate and ryanodine receptor distribution in ankyrin-B (-/-) neonatal cardiomyocytes.

Authors:  Peter J Mohler; Anthony O Gramolini; Vann Bennett
Journal:  J Biol Chem       Date:  2002-01-07       Impact factor: 5.157

Review 2.  Seven-transmembrane-spanning receptors and heart function.

Authors:  Howard A Rockman; Walter J Koch; Robert J Lefkowitz
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

3.  Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference.

Authors:  Seungkirl Ahn; Christopher D Nelson; Tiffany Runyan Garrison; William E Miller; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-11       Impact factor: 11.205

4.  The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex.

Authors:  K A DeFea; Z D Vaughn; E M O'Bryan; D Nishijima; O Déry; N W Bunnett
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

5.  alpha-Thrombin induces rapid and sustained Akt phosphorylation by beta-arrestin1-dependent and -independent mechanisms, and only the sustained Akt phosphorylation is essential for G1 phase progression.

Authors:  Reema Goel; Polly J Phillips-Mason; Daniel M Raben; Joseph J Baldassare
Journal:  J Biol Chem       Date:  2002-03-18       Impact factor: 5.157

6.  Muscarinic supersensitivity and impaired receptor desensitization in G protein-coupled receptor kinase 5-deficient mice.

Authors:  R R Gainetdinov; L M Bohn; J K Walker; S A Laporte; A D Macrae; M G Caron; R J Lefkowitz; R T Premont
Journal:  Neuron       Date:  1999-12       Impact factor: 17.173

7.  Defective lymphocyte chemotaxis in beta-arrestin2- and GRK6-deficient mice.

Authors:  Alan M Fong; Richard T Premont; Ricardo M Richardson; Yen-Rei A Yu; Robert J Lefkowitz; Dhavalkumar D Patel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

Review 8.  G-proteins in growth and apoptosis: lessons from the heart.

Authors:  J W Adams; J H Brown
Journal:  Oncogene       Date:  2001-03-26       Impact factor: 9.867

9.  Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.

Authors:  Giovanni Esposito; Antonio Rapacciuolo; Sathyamangla V Naga Prasad; Hideyuki Takaoka; Steven A Thomas; Walter J Koch; Howard A Rockman
Journal:  Circulation       Date:  2002-01-01       Impact factor: 29.690

10.  Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways.

Authors:  Piyali Dasgupta; Shipra Rastogi; Smitha Pillai; Dalia Ordonez-Ercan; Mark Morris; Eric Haura; Srikumar Chellappan
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

View more
  98 in total

1.  Deciphering biased-agonism complexity reveals a new active AT1 receptor entity.

Authors:  Aude Saulière; Morgane Bellot; Hervé Paris; Colette Denis; Frédéric Finana; Jonas T Hansen; Marie-Françoise Altié; Marie-Hélène Seguelas; Atul Pathak; Jakob L Hansen; Jean-Michel Sénard; Céline Galés
Journal:  Nat Chem Biol       Date:  2012-05-27       Impact factor: 15.040

Review 2.  Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Authors:  Louis M Luttrell; Diane Gesty-Palmer
Journal:  Pharmacol Rev       Date:  2010-04-28       Impact factor: 25.468

Review 3.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

4.  Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization.

Authors:  Kaleeckal G Harikumar; Eyup Akgün; Philip S Portoghese; Laurence J Miller
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

Review 5.  Β-arrestin: a signaling molecule and potential therapeutic target for heart failure.

Authors:  Nabila Noor; Chetan B Patel; Howard A Rockman
Journal:  J Mol Cell Cardiol       Date:  2010-11-11       Impact factor: 5.000

Review 6.  G Protein-coupled Receptor Biased Agonism.

Authors:  Sima Y Hodavance; Clarice Gareri; Rachel D Torok; Howard A Rockman
Journal:  J Cardiovasc Pharmacol       Date:  2016-03       Impact factor: 3.105

7.  D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine.

Authors:  Yudao Shen; John D McCorvy; Michael L Martini; Ramona M Rodriguiz; Vladimir M Pogorelov; Karen M Ward; William C Wetsel; Jing Liu; Bryan L Roth; Jian Jin
Journal:  J Med Chem       Date:  2019-04-18       Impact factor: 7.446

Review 8.  Biased signaling at neural melanocortin receptors in regulation of energy homeostasis.

Authors:  Li-Kun Yang; Ya-Xiong Tao
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-04-19       Impact factor: 5.187

9.  Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.

Authors:  Nikhil M Urs; Simone Bido; Sean M Peterson; Tanya L Daigle; Caroline E Bass; Raul R Gainetdinov; Erwan Bezard; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

10.  Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms.

Authors:  Ashley Bathgate-Siryk; Samalia Dabul; Krunal Pandya; Karlee Walklett; Giuseppe Rengo; Alessandro Cannavo; Claudio De Lucia; Daniela Liccardo; Erhe Gao; Dario Leosco; Walter J Koch; Anastasios Lymperopoulos
Journal:  Hypertension       Date:  2013-11-11       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.